In addition, HtrA2/Omi level change correlates with the XIAP downregulation, caspase-3 activation, and apoptotic response, suggesting that cisplatin resistance probably due to XIAP neutralizing caspase-3 activation and lower cytosolic HtrA2/Omi level in response to cisplatin in human ovarian cancer cells[90]. This evidence concerns the gene CASP3 and ovarian cancer.